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Background: Although the FACED score has demonstrated a great prognostic capacity in 
bronchiectasis, it does not include the number or severity of exacerbations as a separate vari-
able, which is important in the natural history of these patients.
Objective: Construction and external validation of a new index, the E-FACED, to evaluate 
the predictive capacity of exacerbations and mortality.
Methods: The new score was constructed on the basis of the complete cohort for the con-
struction of the original FACED score, while the external validation was undertaken with six 
cohorts from three countries (Brazil, Argentina, and Chile). The main outcome was the number 
of annual exacerbations/hospitalizations, with all-cause and respiratory-related deaths as the 
secondary outcomes. A statistical evaluation comprised the relative weight and ideal cut-off 
point for the number or severity of the exacerbations and was incorporated into the FACED 
score (E-FACED). The results obtained after the application of FACED and E-FACED were 
compared in both the cohorts.
Results: A total of 1,470 patients with bronchiectasis (819 from the construction cohorts and 
651 from the external validation cohorts) were followed up for 5 years after diagnosis. The best 
cut-off point was at least two exacerbations in the previous year (two additional points), mean-
ing that the E-FACED has nine points of growing severity. E-FACED presented an excellent 
prognostic capacity for exacerbations (areas under the receiver operating characteristic curve: 
0.82 for at least two exacerbations in 1 year and 0.87 for at least one hospitalization in 1 year) 
that was statistically better than that of the FACED score (0.72 and 0.78, P,0.05, respectively). 
The predictive capacities for all-cause and respiratory mortality were 0.87 and 0.86, respectively, 
with both being similar to those of the FACED.
Conclusion: E-FACED score significantly increases the FACED capacity to predict future 
yearly exacerbations while maintaining the score’s simplicity and prognostic capacity 
for death.
Keywords: FACED score, E-FACED score, mortality, bronchiectasis, exacerbations
Introduction
Bronchiectasis is a multidimensional disease, and hence, its severity or prognosis 
could not be defined with any precision using a single variable.1–3 Accordingly, 
some recently published multidimensional scores combine clinical, functional, 
microbiological, and radiological variables to evaluate the prognosis and severity of 
bronchiectasis more comprehensively.2,3 One of these scores is the FACED score,3 
an acronym derived from five dichotomized variables (F: forced expiratory volume 
in 1 s [FEV
1
]; A: age; C: chronic colonization by Pseudomonas aeruginosa [PA], 
E: radiological extension [number of pulmonary lobes affected], and D: dyspnea). 
The FACED score is easy to remember and to apply in clinical practice; it presents 
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a range of values of growing severity spanning 0–7 points, 
and it has demonstrated an excellent prognostic capacity for 
mortality (both all-cause and respiratory) in both medium 
and long term, and an excellent capacity to discriminate 
different degrees of severity.4 It also had a good external 
validation in Europe as well as in various Latin American 
countries in bronchiectasis patients with wide-ranging 
etiology and severity and with characteristics different from 
those of the initial cohort.4–6 Nevertheless, some authors 
have found that the FACED score does not predict exacer-
bations accurately.6
One of the key clinical aspects in the prognosis and 
severity of airway diseases is exacerbations, particularly 
serious ones that require hospitalization. In bronchiectasis, 
exacerbations have been associated with higher mortality2 
and a greater impairment of lung function,7 as well as more 
severe forms of the disease.8,9 Furthermore, another important 
aspect of exacerbations in these patients is the substantial 
concomitant health costs.10 As exacerbations are potentially 
preventable, exacerbations and hospitalizations are main 
outcomes in most of the clinical studies that seek to evaluate 
the efficacy and, above all, cost-efficiency of different treat-
ments for bronchiectasis.11–16 Hence, tools that can predict 
future exacerbations and particularly those patients ar risk 
of presenting multiple exacerbations (especially severe ones 
requiring hospitalizations) are required.
Since the FACED score was not constructed with the vari-
able “exacerbations,” the present study aimed to analyze, in 
a wide-ranging series of patients different from the original 
FACED cohort, the prognostic capacity for exacerbations 
(and more particularly for patients with multiple exacerba-
tions) of a new score called E-FACED and compare it with 
that of FACED. It also sought to evaluate whether E-FACED 
also maintains the FACED score’s excellent predictive 
capacity for all-cause and respiratory mortality, as well as 
its capacity to discriminate different degrees of severity of 
bronchiectasis.
Methods
Design
This is an observational, multicenter study of two large 
historical cohorts involving seven teaching centers in Spain 
(construction series) and six teaching centers in Latin America 
(validation series), all with multidisciplinary and protocolized 
monographic bronchiectasis outpatient clinics.
Patients
The Spanish series corresponds with the one used for the 
construction and internal validation of the FACED score. 
It comprised a total of 819 patients with bronchiectasis whose 
characteristics have previously been published.3 This series 
will be used as the construction cohort for the E-FACED. 
Meanwhile, 651 patients with bronchiectasis from six Latin 
American centers (four in Brazil, one in Argentina, and 
one in Chile) who were the subjects for the external valida-
tion of the FACED score will also be used for the external 
validation of the E-FACED score. The characteristics of 
these patients are listed in Table 1. All the patients were 
diagnosed as having bronchiectasis by means of a primary 
diagnosis with HRCT, and they presented a wide range of 
severity, etiologies, and clinical and functional alterations, 
following the criteria described by Naidich et al.17 Patients 
aged ,18 years were excluded, along with those whose vital 
state was unknown at the end of the follow-up. This study 
was approved by the Ethics and Research Committee of each 
participating center (Table S1).
Table 1 Comparative characteristics of the e-FaCeD score’s 
construction and validation cohorts
 Variables Construction 
cohort 
n=819 (%)
Validation 
cohort 
n=651 (%)
age, years 58.7 (17.6) 48.2 (16)
gender, % men 356 (43.5) 214 (32.9)
Body mass index, kg/m2 25.7 (4.7) 22.4 (11.5)
Dyspnea (mMrC) 1.53 (1.16) 1.52 (1.05)
smoking (pack-years) 5.79 (18.1) 4.81 (12.8)
appearance of sputum, n (%)
Mucous 199 (24.5) 177 (27.2)
Mucopurulent 145 (17.7) 229 (35.2)
Purulent 145 (17.7) 124 (19)
respiratory failure, n (%) 83 (10.1) 110 (16.9)
number of affected lobes 2.52 (1.2) 3.37 (1.5)
Idiopathic bronchiectasis, n (%) 310 (37.9) 169 (26)
FeV1, % predicted 68.9 (25.9) 54.7 (22.1)
FVC, % predicted 76.4 (20.3) 67.2 (20.3)
Chronic colonization, n (%)
Pseudomonas aeruginosa 260 (31.8) 259 (39.8)
Haemophilus influenzae 126 (15.4) 67 (10.3)
Multiresistant microorganism 40 (4.9) 40 (6.14)
Isolation of Staphylococcus aureus, n (%) 42 (5.1) 49 (7.5)
Isolation of fungi, n (%) 178 (21.7) 39 (6)
Isolation of nTM, n (%) 23 (2.8) 8 (1.3)
exacerbations (previous year)* 2.52 (2.2) 1.12 (1.4)
hospitalizations (previous year) 0.7 (1.2) 0.4 (0.8)
exacerbations/year (follow-up)* – 0.95 (0.9)
hospitalization/year (follow-up) – 0.3 (0.5)
Chronic treatment, n (%)
systemic antibiotics 59 (7.2) 46 (7.2)
Inhaled antibiotics 146 (17.8) 198 (30.5)
Macrolides 110 (13.4) 113 (17.3)
Oral corticoids 39 (4.7) 25 (3.8)
Death, n (%) 154 (18.8) 95 (14.6)
Note: *The number of hospitalizations (severe exacerbations) are not included.
Abbreviations: mMRC, Modified Medical Research Council; NTM, non-tuberculous 
mycobacterium; FeV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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Variables
The variables recorded in both the construction cohort 
(n=819) and the validation cohort (n=651) were the same 
as those used in the original studies for the construction, 
internal validation, and external validation of the FACED 
score. In other words, the recorded variables corresponded as 
closely as possible to a radiological diagnosis of bronchiecta-
sis. The exacerbations, hospitalizations, and microbiological 
data of the construction cohort pertained to the year prior to 
the patients’ inclusion in the study, while these data were also 
available longitudinally for the validation cohort during the 
5 years of the follow-up. Since there is no standard definition 
of an exacerbation, this study defined an exacerbation as a 
worsening of the respiratory symptoms concomitant with an 
increase in the volume or purulence of sputum that requires 
antibiotic treatment. This enabled identification of the 
number of exacerbations more objectively, according to the 
number of antibiotic treatments prescribed for changes in 
the volume or purulence of sputum or symptoms. Similarly, 
a severe exacerbation was defined as one that was considered 
by the physician to require hospitalization.
Follow-up and main endpoints
Patients from both cohorts were followed up for 5 years 
after the radiological diagnosis of bronchiectasis. After 
these 5 years, their vital state was determined. The number 
of deaths and their causes were identified via the hospitals’ 
computerized records or the corresponding death certificates. 
The main variable was the prognostic capacity for exacerba-
tions in a year, according to different cut-off points as regards 
number and severity. The secondary outcomes were estab-
lished as the predictive capacity for death from any cause 
or from respiratory causes, and the capacity to discriminate 
different degrees of severity.
statistical analysis
The SPSS 20.0 (IBM Corporation, Armonk, NY, USA) 
statistical package was used for all the calculations. The 
quantitative variables were evaluated as mean (standard 
deviation) in cases of normal distribution or as median (inter-
quartile range) in other cases. The qualitative or dichotomic 
variables were evaluated as an absolute value (percentage 
of the total). The normality of the variables was determined 
by means of the Kolmogorov–Smirnov test. Various logis-
tic regressions were made to determine the optimal cut-off 
point for the number of exacerbations and hospitalizations 
that would add the best independent prognostic value to the 
FACED score. The independent values in the construction 
series (n=819), apart from the value of the FACED itself, 
the cut-off points of “at least one”, “at least two”, or “more 
than two” exacerbations or hospitalizations in the year prior 
to inclusion in the study, including a composite of “at least 
two exacerbations or one hospitalization” in the previous 
year. The dependent variable was the number of deaths from 
any cause in the Spanish construction cohort (819 patients). 
The prognostic capacity of the best score for the number or 
severity of the exacerbations was quantified by means of the 
odds ratio (OR; 95% confidence interval [95% CI]), while 
the value of the OR, rounded up to its highest whole value, 
was used as a relative weight for the variable in the new score 
that was formed (E-FACED). In order to simplify the score, 
only different cut-off points were used for the number or 
severity of exacerbations, to make the variable dichotomic, 
as in the original FACED score.
Once the range of the E-FACED score had been cal-
culated and obtained, its prognostic capacity for future 
exacerbations and hospitalizations over the course of a 
year (according to different cut-off points for number and 
severity) was determined by using the external validation 
database (n=651) and calculating the corresponding areas 
under the receiver operating characteristic curve (AUC-
ROC) and 95% CI. A prognostic capacity was considered 
excellent if the AUC-ROC is .80% of the total area.18 
The prognostic capacity of the E-FACED for all-cause and 
respiratory mortality was then calculated, again by using 
the AUC-ROC. All the results were compared with those 
obtained from the application of the FACED score to the 
same series of patients. The ROC curves obtained from the 
E-FACED and FACED scores were compared by means of 
C-statistics. Finally, the Kaplan–Meier curves and the log-
rank test for comparing the curves two by two were used 
to determine the capacity of the new index (E-FACED) to 
discriminate the degree of severity, in order to divide bron-
chiectasis into mild (first tertile), moderate (second tertile), 
or severe (third tertile). In all cases, P,0.05 was considered 
significant.
Results
The construction cohort comprised 819 patients with bron-
chiectasis from the initial Spanish cohort for the construction 
and internal validation of the FACED, whereas the external 
validation cohort (n=651) comprised the Latin American 
cohort for the external validation of the FACED. Data 
from 20 patients from the initial Spanish cohort (2.4%) and 
21 patients from the Latin American cohort (3.1%) were 
not obtained, mainly because of lack of information on their 
vital status at the end of the study (Figure 1). The differen-
tial characteristics of both cohorts are shown in Table 1. 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
10
6.
10
8.
18
2 
on
 0
2-
Se
p-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
278
Martinez-garcia et al
As can be seen, patients in the external validation cohort 
are younger, and they present greater clinical and functional 
severity, a greater radiological extension of bronchiectasis, 
a lower percentage of etiologies of unknown origin, and a 
significantly lower number of exacerbations.
Construction of the e-FaCeD score
Table 2 shows the results of the logistical regressions, which 
included different cut-off points for the number of exacerba-
tions and hospitalizations in the previous year (at least one, 
at least two, or more than two, as well as a composite of 
two exacerbations or at least one hospitalization) to evaluate 
the FACED score’s independent prognostic capacity for 
all-cause mortality. As can be seen, the cut-off point that 
added the most statistically significant prognostic value to the 
FACED score was “at least one hospitalization in the previ-
ous year,” with an OR of 1.8, and so this was the variable 
chosen to be added to the FACED. This process therefore 
added two extra points to the FACED score in cases of at least 
one hospitalization in the previous year, or none in cases of 
no hospitalizations. Table 3 shows that the E-FACED score 
has a range of values of 0–9 points. The three tertiles run-
ning from least to greatest severity are therefore 0–3 points, 
4–6 points, and 7–9 points.
(QUROOHGFRKRUWQ  (QUROOHGFRKRUWQ 
\HDUIROORZXSIURPWKHGDWDRIUDGLRORJLFDOGLDJQRVLVRIEURQFKLHFWDVLV
,QLWLDOFRQVWUXFWLRQFRKRUW)$&('6SDQLVKFRKRUWQ 
([FOXVLRQV/DFNRILQIRUPDWLRQRQYLWDOVWDWHQ 
([FOXVLRQV/DFNRILQIRUPDWLRQRQYLWDOVWDWHQ \HDUVRIDJHQ 
,QLWLDOYDOLGDWLRQFRKRUW/DWLQ$PHULFDQFRKRUWQ 
Figure 1 Flowchart of the study.
Table 2 Different models of logistic regressions to determine the cut-off point for the number and severity of the exacerbations that 
adds the greatest prognostic capacity to the FaCeD score in the construction cohort (n=819)
Model 1 Model 2 Model 3
FaCeD 2.13 (1.87–2.41)
P,0.0001
2.14 (1.89–2.43)
P,0.0001
2.15 (1.89–2.43)
P,0.0001
at least one hospitalization in the previous year, 
n=305 (37.2%)
1.77 (1.22–2.61)
P=0.03
at least two hospitalizations in the previous year, 
n=127 (15.5%)
1.56 (0.94–2.58)
P=0.085
Three or more hospitalizations in the previous year, 
n=68 (8.3%)
1.33 (0.79–1.49)
P=0.17
Model 4 Model 5 Model 6 Model 7
FaCeD 2.45 (2.07–2.88)
P,0.0001
2.99 (2.35–3.82)
P,0.0001
2.99 (2.3–3.8)
P,0.0001
2.3 (1.97–2.67)
P,0.0001
at least one exacerbation in the previous year, 
n=693 (84.6%)
1.95 (0.85–4.4)
P=0.11
at least two exacerbations in the previous year, 
n=525 (64.1%)
1.18 (0.55–2.53)
P=0.66
Three or more exacerbations in the previous year, 
n=326 (39.8%)
1.15 (0.57–2.3)
P=0.69
at least two exacerbations or at least one 
hospitalization in the previous year, n=446 (54.4%)
1.66 (0.82–3.34)
P=0.15
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Prognostic capacity for exacerbations
Table 4 shows how the prognostic capacity of the E-FACED 
score was significantly greater than that of the FACED, in 
both the number and severity (hospitalizations) of the future 
exacerbations over the course of a year. The greatest benefit 
from E-FACED was found in the identification of patients 
with future multiple exacerbations (at least two exacerba-
tions per year [Figure 2], or at least two exacerbations or 
one hospitalization per year).
all-cause mortality: comparison of 
e-FaCeD and FaCeD – construction 
and validation cohorts
Figure 3 shows the AUC-ROC of both the E-FACED and 
FACED scores for all-cause mortality in the initial construc-
tion cohort (n=819). These are 0.87 (0.83–0.91) and 0.87 
(0.82–0.91), respectively, with no significant differences 
between them; they are always .0.80, which means that they 
both present an excellent prognostic capacity. Furthermore, 
in the case of prognostic capacity for respiratory deaths, 
the results were again similarly excellent: the E-FACED 
score presented an AUC-ROC of 0.86 (0.81–0.9), whereas 
the FACED score presented one of 0.82 (0.78–0.87).
Similarly, when both the E-FACED and the FACED 
scores were applied to the series of 651 patients from the Latin 
American cohorts, the AUC-ROCs were 0.84 (0.80–0.88) and 
0.81 (0.77–0.86), respectively, which are as excellent as those 
of the construction cohort, with no statistically significant 
differences between the two. Furthermore, in the case of the 
prognostic capacity for respiratory mortality, the E-FACED 
presented an AUC-ROC of 0.87 (0.83–0.91) and the FACED 
one of 0.84 (0.80–0.88) (Figure 4).
Capacity to discriminate different degrees 
of severity
It was also demonstrated (Figure 5) that the three tertiles of 
both the FACED and the E-FACED scores accurately dif-
ferentiated patients into three groups of increasing severity, 
with no significant differences between the classifications 
created by the FACED and E-FACED scores.
Similarly, the comparative division of this validation 
cohort into three tertiles in both the E-FACED and the 
FACED scores also presented an excellent discrimina-
tory capacity in three groups of increasing severity, with 
no significant differences from the construction cohort 
(Figure 6).
Discussion
According to the results of this study of two large series of 
patients with bronchiectasis, the addition to the FACED score 
of a simple dichotomized variable relating to the presence of 
previous severe exacerbations (hospitalizations; E-FACED 
score) significantly increases the prognostic capacity for 
future exacerbations and hospitalizations over the course of 
1 year, making it a valid score for detecting patients with 
more exacerbated bronchiectasis. Furthermore, the addition 
of this variable does not make the score any more complex 
but does maintain its excellent prognostic capacity for both 
all-cause and respiratory mortality, while also retaining the 
capacity of FACED score to discriminate different degrees of 
severity. By adding a variable that is potentially modifiable 
or preventable with treatment, the E-FACED would broaden 
Table 3 The e-FaCeD score
Variable Values Points
at least one severe exacerbation 
in previous year
no
Yes
0
2
FeV1 (% predicted) at least 50%
,50%
0
2
age ,70 years
at least 70 years
0
2
Chronic colonization by 
Pseudomonas aeruginosa
Yes
no
1
0
extension (n° of pulmonary 
lobes affected)
1–2 lobes
.2 lobes
0
1
Dyspnea (mMrC) 0–II 0
III–IV 1
range 0–9 points
Abbreviations: FeV1, forced expiratory volume in 1 s; mMRC, Modified Medical 
research Council.
Table 4 Comparison between the prognostic capacity of e-FaCeD and FaCeD for the number and severity of exacerbations in the 
validation cohort (n=651)
FACED E-FACED P-value
at least one exacerbation per year (n=228; 35%) 0.70 (0.67–0.75) 0.76 (0.72–0.80) ,0.05
at least two exacerbation per year (n=117; 17.9%) 0.72 (0.68–0.78) 0.82 (0.78–0.87) ,0.05
at least one hospitalization per year (n=56; 8.6%) 0.82 (0.78–0.87) 0.89 (0.85–0.92) ,0.05
at least two exacerbations per year or one 
hospitalization per year (n=150; 23%)
0.78 (0.74–0.82) 0.87 (0.83–0.90) ,0.05
Note: Data are presented as AUC-ROC (95% confidence interval).
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its clinical applicability and its potential use in research 
studies on new treatments for bronchiectasis.
The FACED score is a very simple (and even memoriz-
able) multilevel system for evaluating (without any need for 
a computer) the initial severity and prognosis of patients with 
bronchiectasis.3 However, one of its limitations is the fact 
that it does not cover exacerbations. And although there is 
little literature on this topic, some important studies have 
shown this variable to have a decisive impact, especially in 
its more severe forms, on both the severity and prognosis 
of bronchiectasis.2,6,7 In this respect, Chalmers et al,2 in a 
study of the construction and validation of the BSI (Bron-
chiectasis Severity Index) score, observed that both previ-
ous exacerbations (at least two exacerbations; HR (hazard 
ratio) 2.03 [1.02–4.03]) and, above all, severe exacerbations 
(hospitalization; HR 2.43 [1.02–4.03]) were significantly 
associated with an increase in all-cause mortality, with a very 
substantial relative weight (above all severe exacerbations) in 
the final value of the score. Although the BSI score is more 
complex than the FACED, it has demonstrated an excellent 
prognostic capacity for exacerbations/hospitalizations in 
patients with bronchiectasis.2 Moreover, Martínez-García 
et al have demonstrated that, over and above any chronic 
bronchial infection or presence of systemic inflammation, 
severe exacerbations were capable of producing a steep 
drop in lung function, of up to 120 mL of FEV
1
 in a year – 
more than double the mean observed overall in patients with 
bronchiectasis (~50 mL/year).7
This substantial impact of exacerbations on bron-
chiectasis patients can be explained by the increase in 
diagnoses,19 related mortality,20 and hospitalizations due 
to bronchiectasis21,22 in recent years, even in industrial-
ized countries, despite the excellent therapeutic arsenal at 
disposal. Ringshausen et al,21 for example, found a rise 
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Figure 2 Comparative aUC-rOC for the prediction of at least two exacerbations 
per year.
Abbreviation: aUC-rOC, areas under the receiver operating characteristic curve.
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Figure 3 Comparison of the prognostic capacity of the FaCeD and e-FaCeD scores for (A) all-cause mortality and (B) respiratory mortality in the initial cohort of 
patients (n=819).
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in hospitalization from 9.4 to 39.4/100,000 inhabitants, 
especially in women and the elderly. Similar findings have 
been observed in the USA, with an annual increase of 
2.5%–3% in the period 1993–2006.22
Furthermore, patients who present the greatest number or 
severity of exacerbations are also the ones who accumulate 
a higher percentage of health costs. De la Rosa et al10 found 
that the annual cost of treating a bronchiectasis patient in 
Spain in 2012 was 4,671 euros, and ~10,000 euros in cases 
of severe bronchiectasis (FACED 5–7 points), with exacer-
bations being one of the variables that explained a higher 
percentage of cost. Thus, the group of patients with more 
than two exacerbations (21.5%) was responsible for 34.5% 
of the total cost of the 456 patients included, while those 
patients who required two or more hospitalizations (5.7%) 
were responsible for 20.4% of the total cost. Therefore, 
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Figure 4 Comparison of the prognostic capacity of the FaCeD and e-FaCeD scores for all-cause and respiratory mortality in the validation cohort (n=651).
Note: (A) all-cause mortality and (B) respiratory mortality.
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Figure 5 Comparison of the discriminatory capacity of the (A) FaCeD and (B) e-FaCeD scores in groups of increasing severity in the initial cohort (n=819).
Notes: (A) FaCeD score: mild: 0–2 points, moderate: 3–4 points, and severe: 5–7 points. log-rank test: mild bronchiectasis versus moderate bronchiectasis 51.2, P,0.0001; 
mild versus severe 309.9; P,0.0001; and moderate versus severe 64.6, P,0.0001. (B) e-FaCeD score: mild: 0–3 points, moderate 4–6 points, and severe 7–9 points. 
log-rank test: mild bronchiectasis versus moderate bronchiectasis 111.2, P,0.0001; mild versus severe 287.7; P,0.0001; and moderate versus severe 26.5, P,0.0001.
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even without any definition of an exacerbatory clinical 
phenotype in bronchiectasis, the impact of exacerbations 
on these patients calls for a simple and prompt identification 
of the type of patients who will present a higher number or 
greater severity of exacerbations in the future.
In this study, the E-FACED score (a simple score that only 
adds to the FACED score one easily memorized dichotomic 
variable pertaining to the presence of hospitalizations in the 
year prior to the patient’s diagnosis) presents advantages over 
the FACED. While maintaining the substantial prognostic 
capacity of the latter, for all-cause and respiratory mortality 
and for discrimination of degrees of severity, the E-FACED 
is capable, without accruing any greater complexity, of sig-
nificantly improving the early identification of patients who 
will have at least two exacerbations or one hospitalization 
over the course of a year, or both, despite receiving treat-
ment. This means that it is important to establish a prompt 
and thorough preventive strategy for these patients.
Moreover, another advantage of the E-FACED over 
the FACED is its greater susceptibility to change after the 
administration of different treatments. This may make it more 
suitable for research studies, both because it incorporates the 
main variable customarily used in randomized clinical trials 
(the number and severity of exacerbations) and because it 
presents a great prognostic capacity for these factors.
Although the present study has several significant strengths, 
particularly large numbers of patients being included in 
both the series (construction and external validation), it 
also presents a number of noteworthy limitations. On the 
one hand, exacerbations have been defined by the need for 
antibiotic treatment prescribed for changes in the volume or 
purulence of sputum or in the symptoms. They are therefore 
open to a more objective classification, although it should 
be emphasized that smaller exacerbations that do not require 
such treatment have also been recorded. It is nevertheless 
believed that the impact of this limitation on the conclusion 
cannot be very significant as most patients with exacerbations 
of bronchiectasis are treated with antibiotics,3 and further-
more, more severe exacerbations have the greatest impact on 
patients.2,6 On the other hand, the E-FACED was constructed 
using different cut-off points as regards the number of hos-
pitalizations in the year prior to the patient’s inclusion in the 
study, but no longitudinal data on the hospitalizations in the 
construction cohort (n=819) in the subsequent years were 
available. Such longitudinal data on the number of yearly 
exacerbations and hospitalizations are available, however, 
for the validation cohort (n=651), and, thanks to the way the 
E-FACED was constructed, it has demonstrated an excellent 
prognostic capacity. Moreover, we cannot exclude the influ-
ence of the chronic treatments used on clinical outcomes, 
especially in the number or severity of exacerbations. How-
ever, this is a limitation of all studies that include historical 
cohorts of patients with data recorded longitudinally from 
the time of diagnosis. Furthermore, no treatment has yet 
been proved to have any influence on the natural history of 
the disease. Finally, data were not obtained from 2.4% of 
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Figure 6 Comparison of the discriminatory capacities of the (A) FaCeD and (B) e-FaCeD scores in groups of increasing severity in the validation cohort (n=651).
Notes: (A) FaCeD score: mild: 0–2 points, moderate: 3–4 points, and severe: 5–7 points. log-rank test: mild bronchiectasis versus moderate bronchiectasis 43.3, P,0.0001; 
mild versus severe 138.9; P,0.0001; and moderate versus severe 23.4, P,0.0001. (B) e-FaCeD score: mild: 0–3 points, moderate: 4–6 points; and severe: 7–9 points. 
log-rank test: mild bronchiectasis versus moderate bronchiectasis 71.3, P,0.0001; mild versus severe 201.2; P,0.0001; and moderate versus severe 24.1, P,0.0001.
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patients from the original FACED score cohort and 3.1% 
of patients from the Latin American series, mainly because 
of lack of information on their vital status, but such a small 
percentage of missing data cannot be expected to change the 
conclusion of the study.
Conclusion
In conclusion, the E-FACED offers a more versatile alter-
native to the FACED that is more susceptible to variations 
after medication, while maintaining the excellent prognostic 
capacity of the latter for mortality and its capacity to discrimi-
nate degrees of severity, without increasing the complexity of 
the score. Moreover, it presents a greater prognostic capacity 
for exacerbations and hospitalizations, especially in patients 
in which these are more frequent. Although further studies are 
required to investigate the applicability of the E-FACED in 
research studies, it is considered that the greater capacity of 
this score for change makes it more suitable than the FACED 
for use in clinical trials to evaluate different treatments for 
bronchiectasis.
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